Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482794 · ClinicalTrials.gov registry record
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
A clinical trial of Antiphospholipid Syndrome, sponsored by Duke University.
- Recruiting
- Registry status
- 2,800
- Enrollment target
- 1
- Study location
NCT00482794: Recruiting study of Antiphospholipid Syndrome, sponsored by Duke University.
NCT00482794 is a study of Antiphospholipid Syndrome that is actively recruiting participants, run by Duke University. The registered enrollment target is 2,800 participants, above the 984-participant average among 6 other Antiphospholipid Syndrome trials with a reported enrollment target (185% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482794, a study of Antiphospholipid Syndrome, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 2,800 participants
- Enrollment target
- 1
- Study location
Study Summary
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2006-06 |
| Est. Completion | 2028-03 |
What NCT00482794 shows while recruiting
NCT00482794 is an observational study that tracks outcomes without assigning an intervention. Its 2,800 participants enrollment target places it among the larger protocols in the corpus, above the 984-participant average among 6 other Antiphospholipid Syndrome trials with a reported enrollment target (185% higher).
The record links to 1 condition, with Antiphospholipid Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00482794 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00482794 about?
NCT00482794 is a clinical study titled "Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome". Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk f...
What is the current status of trial NCT00482794?
This trial is currently recruiting. The enrollment target is 2,800 participants. The study started on 2006-06. Estimated completion is 2028-03.
What conditions does trial NCT00482794 study?
This clinical trial studies the following conditions: Antiphospholipid Syndrome.
Who is sponsoring clinical trial NCT00482794?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00482794 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antiphospholipid Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
RECRUITING
-
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
RECRUITING
-
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
COMPLETED · Phase 2
-
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
COMPLETED
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia